Abstract
Talimogene laherparepvec (T-VEC) is an oncolytic virus, approved for the treatment of stage IIIb-IVM1a melanoma with injectable disease (cutaneous, subcutaneous or lymphatic). It is a modified herpes simplex virus type 1 that induces tumor-specific T-cell responses via reduction of virally mediated suppression of antigen presentation, stimulation of viral pathogenicity and enhancement of tumor-selective replication. Response rates up to 82.6% have been reported for stage III disease. Acral lentiginous melanoma (ALM) is a rare subtype of melanoma with a poor prognosis. Here, we present a case of an elderly and frail patient with primary ALM who refused surgical treatment and consented to receive T-VEC as first-line drug therapy. After 10 courses of treatment, a histopathologically confirmed complete response was achieved. To our knowledge, this is the first case ever reported in which a primary ALM is (successfully) treated with T-VEC.
References
Nov 21, 1997·Annals of Surgical Oncology·G R EvansS Mosser
Jan 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason A ZellHoda Anton-Culver
Apr 22, 2009·Archives of Dermatology·Porcia T BradfordMargaret A Tucker
Mar 21, 2012·Archives of Dermatology·Mark A HydeGlen M Bowen
Jul 13, 2012·Journal of Cutaneous Medicine and Surgery·Jessica G WongMarni C Wiseman
Oct 2, 2012·American Journal of Surgery·Michael E EggerCharles R Scoggins
Sep 5, 2014·BMJ Case Reports·Gloria R SueDeepak Narayan
Sep 25, 2014·Clinical and Experimental Dermatology·I SavareseV De Giorgi
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Nov 26, 2015·Cancer Treatment and Research·James S Goydos, Steven L Shoen
Sep 24, 2016·Journal for Immunotherapy of Cancer·Hasan RehmanHoward L Kaufman
Oct 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jason ChesneyHoward L Kaufman
Jun 15, 2018·Lancet·Xiao Ke Liu, Jun Li
Dec 12, 2018·Advances in Therapy·Peter MohrKarly S Louie
Jan 29, 2019·Journal of the American College of Surgeons·Raphael J LouieDavid W Ollila
Jan 30, 2019·International Journal of Cancer. Journal International Du Cancer·Viola FrankeAlexander C J van Akkooi
Aug 14, 2019·Melanoma Management·Matthew C PerezLeon Raskin
Nov 7, 2019·Expert Opinion on Biological Therapy·Kristy Broman, Jonathan Zager